Glyco680mg - Management of glycemia

Glyco680mg is a combination of plant extracts and minerals formulated to target key drivers of normal glucose management. Glyco680mg is clinically proven to reduce postprandial glucose levels, contributing to overall metabolic homeostasis. Supported by an acute clinical study. 680 mg/day. 

Glyco680mg - Key features

  • Combines polyphenols with an α‑amylase inhibitor, chromium, and zinc
  • Formulated to support glucose balance
  • Helps maintain balanced glucose levels after meals

Science supporting Glyco680mg

An acute clinical study with the primary objective of evaluating the reduction in postprandial glucose levels was conducted following a randomised, single-blind, crossover design.

Characterisation

Glyco680mg has been formulated from a selection of polyphenols from olive and blackcurrant, carefully chosen through a clinical screening for their ability to manage normal post-prandial glycemia.

The formulation has been enriched in essential minerals such as zinc and chromium, and a white kidney bean extract standardised for its amylase inhibition capacity at 500 mg per day. Each of the ingredients chosen in the formulation of Glyco680mg plays a critical role in managing the key drivers of prediabetes.  

Active compounds:
Secoiroids (incl. Oleuropein)             ≥ 3.90%
Total anthocyanins                              ≥ 0.90%
Chromium                                             ≥ 150 ppm
Zinc                                                          ≥ 4500 ppm
Alpha-amylase inhibiting activity   ≥ 3500 AAIU/g

Composition: White kidney bean extract (Phaseolus Vulgaris L.), Arabic gum (Acacia Senegal L.), Green olive leaf extract (Olea europaea L.), Blackcurrant extract (Ribes nigrum L.), Zinc bisglycinate, Chromium picolinate.

Recommended daily dosage: 680 mg

Clinically supported benefits

Randomised, single-blind, crossover and placebo-controlled study.

YEAR & DURATION 2021
Acute study
POPULATIONS

10 subjects
Men and women
BMI> 27-32 kg/m2
Age: 20-50 years old

PROTOCOLS

Postprandial glucose levels
Glycemia 100-125 mg/dL
Pre-diabetic subjects

INTAKES CAPSULES
Glyco680mg or placebo

Studies on Glyco680mg have shown significant reductions in postprandial glucose levels.  

     

  • Measure of postprandial glucose concentration of the subjects revealed a significant change in postprandial glucose kinetics between the placebo and Glyco680mg groups.

  • The change in the area under the curve for postprandial glucose between the Glyco680mg group and placebo was significant, measuring the variations in glycaemia between pre- and postprandial conditions.

Glyco680mg is safe

No adverse events linked to Glyco680mg supplementation have been recorded.

Certifications & Compliance

Non-GMO, gluten-free, suitable for vegetarians.

References

CLINICAL TRIALS
Publication pending, report available upon request

MECHANISTIC STUDIES
Publication pending, report available upon request

This website is intended to provide information about Biotexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.